Meta-analysis of clinical trials with copolymer 1 in multiple sclerosis

European Neurology

Volumn 43, Issue 4, 2000, Pages 189-193

  La Mantia, L ^a   Milanese, C ^a   D'Amico, R ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Copolymer 1; Glatiramer acetate; Multiple sclerosis; Relapsing remitting course

Indexed keywords

GLATIRAMER;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SHORT SURVEY;

EID: 0034102133     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000008174     Document Type: Short Survey

References (23)

1. Ben-Hun A, Mendel I, Bakimer R, Fridkis-Hareli M, Teitelbaum D, Arnon R, Sela M, Kerlero de Rosbo N: The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenetic: Effect of copolymer 1 on MOG-induced disease. J Neurol 1996;243:S14-S22.
2. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Seal M: Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 1974;3:256-262.
3. Abramsky O, Teitelbaum D, Arnon R: Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. J Neurol Sci 1977;31: 433-438.
4. Besson G, Carpentier F: New therapeutic agents in the management of multiple sclerosis. Presse Méd 1998;27:2032-2035.
5. L'Abbé Ka, Detsky AS, O'Rourke K: Metaanalysis in clinical research. Ann Intern Med 1987;107:224-233.
6. Counsell CE, Fraser H, Sandercock PAG: Archie Cochrane's challenge: Can periodically updated reviews of all randomized controlled trials relevant to neurology and neurosurgery be produced? J Neurol Neurosurg Psychiatry 1994;57:529-533.
7. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
8. McDonald WI, Halliday AM: Diagnosis and classification of multiple sclerosis. Br Med Bull 1977;33:4-9.
9. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
10. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
11. Peto R: Why do we need systematic overviews of randomized trials? Stat Med 1987;6:233-240.
12. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merrian A, Wassertheil-Smoller S, Spada V, Weiss W, Arnon R, Jacobson I, Teitelhaum D, Sela M: A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317: 408-414.
13. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS, and the Copolymer 1 Multiple Sclerosis Study Group: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276.
14. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstern J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS, and the Copolymer 1 Multiple Sclerosis Study Group: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-708.
15. Baumhefner RW, Tourtellotte WW, Syndulko K, Shapshak P, Osborne M, Rubinstein G: Copolymer 1 as therapy for multiple sclerosis: The cons. Neurology 1988;38:69-72.
16. Bornstein MB, Miller AI, Teitelbaum D, Arnon R, Sela M: Multiple sclerosis: Trial of a synthetic polypeptide. Ann Neurol 1982;11:317-319.
17. Korezyn AD, Nisipeanu P: Safety profile of copolymer 1: Analysis of cumulative experience in the United States and Israel. J Neurol 1996;243:S23-S26.
18. Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, Spada V, Weiss W, Appel S, Rolak L, Harati Y, Brown S, Arnon R, Jacobson I, Teitelbaum D, Sela M: A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991;41: 533-539.
19. Cohen JA, Grossman RI, Udupa JK, Samarasekera S, Miki Y, Polansky M, Constatinescu SC, Kolson DL, Silberberg DH, Gonzales-Scarano F, Johnson KP: Assessment of the efficacy of copolymer 1 in the treatment of Multiple-Sclerosis by quantitative magnetic resonance imaging (abstract). Neurology 1995;45:A418.
20. Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, Inglese M, Ferrari A, Sormani MP, Ottonello C, Levrero F, Uccelli A, Bruzzi P: Effect of copolymer 1 on serial gadoliniumenhanced MRI in relapsing-remitting multiple sclerosis. Neurology 1998;50:1127-1133.
21. Weinstein A, Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD: Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56:319-324.
22. Comi G, Filippi M for the Copaxone MRI Study Group: The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, placebo-controlled study extended by open-label treatment. American Academy of Neurology, 51st Annual Meeting (abstract). Neurology 1999;52(suppl 2):A289.
23. Flechter S, Vardi J, Robey JM: Comparison of efficacy between glatiramer acetate and interferon beta lb in multiple sclerosis patients: A two-year follow-up study. American Academy of Neurology, 51st Annual Meeting (abstract). Neurology 1999;52(suppl 2):A497.